BULLISH WEDGE CONFIRMED ABOUT TO BREAK OUTTTTTTTTTTTTTTTTTTTTTTTTTTTT
IPCI - Intellipharmaceutics - Page 4
IPCI IS THE BEST AND THE MOST UNDERVALUED UNKNOWN GEM IN THE BIOTECH SECTOR BUT PLEASE DO YOUR OWN RESEARCH ! GLTA
This Unknown ULTRA LOW FLOAT Stock awaiting 6 FDA approvals which will be all approved within 10 months.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including a potential Blockbuster .
Market Cap 45 Mil / Cash 7.5 M / Burn-rate 4.5 M per Year = Enough Cash until Profitability which will happen THIS YEAR .
3-4 FDA APPROVALS IN 2012 = $10++ EASILY FOLKS ! GLTA
This sleeping giant will be another billion dollar company in the near term .
Market Cap:$ 45 M
Cash: $ 7.5 M
Shares Out: 15.9 Mil..(10 Mil Shares held by Insiders/Institutions)
SUPER LOW FLOAT: 4 M
Intellipharmaceutics now has six ANDAs being reviewed by the FDA for approval, with reported sales by others for branded and generic versions of these products being approximately $6.6 billion for the 12 months ended September 2011. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.
Latest Presentation :
New Article (IPCI worth $15++ per share )
CEO says multiple deals, FDA approvals and more filings are in the works
Roth starts Intellipharmaceutics at buy
Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating , saying the emerging generics company could launch four new products in the coming 12-to-18 months.
“We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed at $2.97 on Wednesday.
Intellipharmaceutics’ four upcoming product launches include generics of Focalin XR, Effexor XR, Protonix, and Glucophage XR. The lead product, Focalin XR for attention deficit hyperactivity disorder, is partnered with generic leader Par Pharmaceuticals.
“This product pipeline produces branded revenue near $5 billion and we believe that these generic offerings could produce near $100 million in end-user revenue potential for Intellipharmaceutics,” Mr. Henry points out.
He figures product launches could boost revenue from about $1 million in 2011 to nearly $20 million in 2013, with the company crossing over into profitability in the fourth quarter of 2012. For 2013, he predicts earnings per share of 30 cents.
Intellipharmaceutics also has an “entrant in the high-growth area of abuse-resistant opioids, which could be a multi-billion dollar market,” Mr. Henry said. “Although early, this gives investors another way to win, in our opinion.”
Another Blockbuster On Deck for Intellipharmaceutics?
By M.E. Garza
We were surprised to see that shares of Intellipharmaceutics (IPCI) barely reacted after the company announced that it has retained the services of Doll Consulting's David S. Doll, to assist with the commercialization of products in its controlled-release generic drug portfolio as well as its New Drug Application (NDA) portfolio.
If the news was not fully digested as a positive development, then its a safe bet that investors also missed the “Easter egg” in Monday's press release. Fellow nerds may know that a virtual Easter egg is an intentional hidden message, in-joke or feature in movies, books or video games. The term draws a parallel with the custom of the Easter egg hunt observed which thrives on discovering hidden surprises. We’ll come back to the Easter egg momentarily.
As we’ve saying, IPCI is an intriguing biotech play with an extremely low float. The stock ran to $6 after we issued a detailed report describing why we expect it to become a multi-bagger. Every time it dips, we’ve been encouraging our readers to diligently accumulate more shares. They’d be smart to do so in light of Monday’s news.
First, it tells us that the firm is finally about to enter the commercialization phase. It also suggests that FDA approvals are on the way and as we've said recently, that positions IPCI well for partnership offers for the distribution of their super generic drug formulations. Intellipharmaceutics’ master drug formulator and CEO, Isa Odidi and his team have been busy filing controlled released versions with the FDA.
The news also tells us that Odidi is willing to do what it takes to make sure investors in the company get back the best value they can. By enlisting Doll, Odidi brings on an expert in commercial pharmaceutical operations with an impressive resume spanning over 26 years in the pharmaceutical industry. Doll’s stint as executive vice president, commercial operations at Impax Laboratories (IPXL) shows that he can successfully negotiate lucrative, long-term agreements with the major pharmaceutical companies who want IPCI’s products. Doll has already done it on multiple occasions with TEVA (TEVA), Shire Plc. (SHP), Novartis (NVS), Purdue Pharma, Schering (BYERF.PK), Wyeth (WYE), and others.
Here’s a direct quote from Monday’s press release. See if you can spot the Easter egg:
"We now have four products filed with the FDA for the purpose of obtaining regulatory approval in the U.S. [ANDA's for Focalin XR, Effexor XR, Protonix, Glucophage XR] and expect to file at a minimum an additional two products this year," stated Dr. Isa Odidi, CEO and co-Founder of Intellipharmaceutics. "Given our progress last year, our anticipated growth moving forward, and an increased focus on partnering due to our advancing pipeline, Dave Doll, with his impressive track record in business development and commercialization, is an excellent addition to our team."
Did you see it? If you spotted the reference in Odidi’s quote to “Glucophage XR,” then you’re on to something.
This is the first time we have ever seen Glucophage XR mentioned in any public disclosure as a drug that Intellipharmaceutics has submitted to the FDA. Did we miss the press release disclosing this previously or has that news yet to make the wires?
People had been betting that Odidi would be going after yet another big market drug, but I don’t think anyone had guessed that it would be the first-line drug of choice for the treatment of type 2 diabetes- Glucophage. Bristol Myers Squibb (BMY) and others have made billions marketing the drug. Diabetes affects roughly 6% of the adult population; somewhere north of 246 million people worldwide, and the number is expected to rise to 380 million by 2025. With doctors and experts at the International Diabetes Federation recommending that drug remains a drug of choice for first-line therapy of type 2 diabetes, there is clearly plenty of room in the market for the version IPCI has submitted for approval.
Odidi has also told the market that IPCI will be filing at least two more products this year. That gives us more reason to be excited. Smart money says those will be multi-billion dollar drugs as well.
As we pointed out in our initial report, Investors are excited about a potential NDA filing with the FDA for Abuse Resistant Oxycontin. Controlled-release oxycodone drugs had U.S. sales of approximately $2 billion and IPCI's drug delivery platform (branded Rexista) is a novel, paste-in-a-capsule dosage form designed to be a deterrent to the well-documented abuses. Last summer, the company advised investors that it had taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of the abuse-deterrent formulation and that the manufacture of clinical batches using that equipment had commenced. It is worth noting that the company's Rexista technology is applicable to additional opioid drug candidates like oxymorphone, hydrocodone, and morphine.
The Intellipharmaceutics story is getting more interesting every day.
Disclosure: Long IPCI
|% Held by Insiders:||39.16%|
|% Held by Institutions:||0.60%|
|Shares Short (as of May 31, 2012):||125.01K|
|Short Ratio (as of May 31, 2012):||10.10|
VERY SOLID PRESENTATION GIVEN AND HERE IS THE LINK FOR THE PDF SUPER JUICY PEOPLE...GET IN NOW!!!
Here is another link to view the Presentation since the megabytes got EXCEEDED!!!
Intellipharmaceutics International Inc. : Intellipharmaceutics Achieves a 2012 Goal by Filing Two ANDAs -- Generic Forms of Keppra XR(R) and Pristiq(R)
09/05/2012 | 09:56am US/Eastern
TORONTO, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the achievement of another of its previously announced development goals for 2012 with its filing of two Abbreviated New Drug Applications ("ANDAs") with U.S. Food and Drug Administration ("FDA"). The first ANDA is for a generic version of the marketed drug Keppra XR® (levetiracetam extended-release tablets), an antiepileptic drug indicated for the treatment of partial onset seizures in patients with epilepsy. The second ANDA is for a generic version of the marketed drug Pristiq® (desvenlafaxine extended-release tablets), a selective serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder. According to Wolters Kluwer Health, U.S. sales for the 12 months ending July 2012 for Keppra XR® were approximately $149 million and for Pristiq® were approximately $626 million.
"We are pleased to achieve our goal for 2012 of two additional ANDA filings for the year," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "Our Hypermatrix technology platform is versatile, providing opportunities to replicate release profiles of many drugs with different physical and chemical properties. We continue to expand our controlled-release generic product pipeline, which we believe may provide multiple opportunities for potential revenue generation."
Intellipharmaceutics has now announced eight ANDAs as having been filed with the FDA, with reported sales by others for branded and generic versions of these products being approximately $4.5 billion for the 12 months ended July 2012. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway. There can be no assurance as to whether or when the FDA will approve any Intellipharmaceutics' application.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of product candidates in various stages of development, including eight ANDAs as having been filed with the FDA, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes, pain and infection.
Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "intends," "could," or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies and product candidates as compared to others, our ability to maintain and establish intellectual property rights in our drug delivery technologies and product candidates, the actual size of the potential markets for any of our product candidates compared to our market estimates, our selection and licensing of product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, the timing and amount of insurance reimbursement for our products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, and the manufacturing capacity of third-party manufacturers that we may use for our products. Additional risks and uncertainties relating to the Company and our business can be found in the "Risk Factors" section of our latest annual information form and latest Form 20-F, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Intellipharmaceutics 30 Worcester Road Toronto, ON Canada M9W 5X2 www.intellipharmaceutics.com Shameze Rampertab Vice President Finance & CFO 416-798-3001 x106 firstname.lastname@example.org
Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.
Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."
For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.
Shares of IntelliPharmaCeutics International closed at $2.86 yesterday, with a 52 week range of $2.40-$3.82.